- Home
- EQX vs ADMA Comparison
EQX vs ADMA Comparison
Compare EQX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- ADMA
- Stock Information
- Founded
- EQX 2007
- ADMA 2004
- Country
- EQX Canada
- ADMA United States
- Employees
- EQX N/A
- ADMA N/A
- Industry
- EQX Precious Metals
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EQX Basic Materials
- ADMA Health Care
- Exchange
- EQX Nasdaq
- ADMA Nasdaq
- Market Cap
- EQX 6.1B
- ADMA 5.1B
- IPO Year
- EQX N/A
- ADMA N/A
- Fundamental
- Price
- EQX $8.24
- ADMA $17.36
- Analyst Decision
- EQX
- ADMA Strong Buy
- Analyst Count
- EQX 0
- ADMA 3
- Target Price
- EQX N/A
- ADMA $27.67
- AVG Volume (30 Days)
- EQX 13.6M
- ADMA 3.3M
- Earning Date
- EQX 08-13-2025
- ADMA 08-06-2025
- Dividend Yield
- EQX N/A
- ADMA N/A
- EPS Growth
- EQX N/A
- ADMA 469.09
- EPS
- EQX N/A
- ADMA 0.85
- Revenue
- EQX $1,905,732,000.00
- ADMA $474,174,000.00
- Revenue This Year
- EQX $59.63
- ADMA $21.08
- Revenue Next Year
- EQX $44.19
- ADMA $25.98
- P/E Ratio
- EQX N/A
- ADMA $20.24
- Revenue Growth
- EQX 74.31
- ADMA 43.58
- 52 Week Low
- EQX $4.95
- ADMA $13.50
- 52 Week High
- EQX $8.28
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- EQX 74.88
- ADMA 47.80
- Support Level
- EQX $8.07
- ADMA $16.87
- Resistance Level
- EQX $8.28
- ADMA $17.58
- Average True Range (ATR)
- EQX 0.29
- ADMA 0.58
- MACD
- EQX 0.08
- ADMA 0.04
- Stochastic Oscillator
- EQX 97.01
- ADMA 74.65
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.